Valuation: IN8bio, Inc.

Market Cap 9.55M 8.29M 7.76M 7.1M 13.4M 910M 13.58M 90.79M 35.63M 455M 35.86M 35.08M 1.51B P/E 2026 *
-0.78x
P/E 2027 * -0.92x
Enterprise Value 9.55M 8.29M 7.76M 7.1M 13.4M 910M 13.58M 90.79M 35.63M 455M 35.86M 35.08M 1.51B EV / Sales 2026 *
-
EV / Sales 2027 * 11.5x
Free-Float
86.6%
Yield 2026 *
-
Yield 2027 * -
1 day-1.91%
1 week-10.19%
Current month-6.29%
1 month-32.65%
3 months-38.61%
6 months-51.26%
Current year-58.55%
1 week 0.9
Extreme 0.9
1.08
1 month 0.9
Extreme 0.9
1.46
Current year 0.9
Extreme 0.9
2.73
1 year 0.9
Extreme 0.9
2.73
3 years 0.9
Extreme 0.9
74.4
5 years 0.9
Extreme 0.9
309.57
10 years 0.9
Extreme 0.9
309.57
Manager TitleAgeSince
Chief Executive Officer 50 2015-10-31
Chief Tech/Sci/R&D Officer 72 2018-10-31
Director of Finance/CFO 43 2021-02-07
Director TitleAgeSince
Director/Board Member 50 2015-10-31
Director/Board Member 68 2019-06-30
Director/Board Member 64 2021-08-03
Date Insider Type Main position Quantity % Market Cap.
5/9/26 Free

Director

22,000 0.2234%
2/4/26 Free

Founder

72,000 0.7372%
2/4/26 Free

Chairperson

80,000 0.8192%
Change 5-day change 1-year change 3-year change Capi.($)
-1.91%-10.19%-53.81%-97.33% 9.74M
-3.25%+13.72%+52.49%+88.86% 64.9B
+0.69%+0.96%+29.39%+68.41% 54.05B
-1.07%-1.79%-18.07%-14.36% 23.16B
+33.86%+30.60%+19.14%+502.77% 21.46B
+6.57%+13.68%+46.70%+0.43% 21.25B
-0.79%+1.79%+36.31%-25.84% 17.94B
-3.37%+25.85%+213.21%+369.13% 17.03B
+4.43%+9.24%+32.19%+665.94% 14.99B
-7.94%-6.74%+38.42%+157.52% 14.25B
Average +2.67%+4.90%+39.60%+171.55% 24.9B
Weighted average by Cap. +2.17%+6.97%+45.34%+152.50%

Financials

2026 *2027 *
Net sales - 830K 720K 674K 617K 1.16M 79.04M 1.18M 7.89M 3.1M 39.49M 3.12M 3.05M 131M
Net income -22.29M -19.35M -18.12M -16.57M -31.28M -2.12B -31.69M -212M -83.17M -1.06B -83.7M -81.88M -3.53B -25.76M -22.36M -20.94M -19.15M -36.15M -2.45B -36.63M -245M -96.12M -1.23B -96.73M -94.63M -4.08B
Net Debt - -
Logo IN8bio, Inc.
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Employees
-
Date Price Change Volume
26-08-06 US$0.9699 -1.91% 71,865
26-08-05 US$0.9888 +2.99% 39,883
26-08-04 US$0.9601 +0.01% 37,736
26-08-03 US$0.9600 -7.25% 152,091
26-07-31 US$1.035 -4.17% 57,627
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9699USD
Average target price
6.250USD
Spread / Average Target
+544.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INAB Stock